Regensburg

• Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting
  2025-522052-13-00 10 2025-12-24 Framework for Optimizing, Refining, and Unifying Management of HSCT in
• A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting
  2024-512753-24-00 5 2025-08-05 Acute Myeloid Leukemia (AML)
• AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Pri … Recruiting
  2024-516525-31-01 5 2025-07-14 Primary Biliary Cholangitis
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML … Recruiting
  2024-512733-32-00 5 2025-03-31 Acute Myeloid Leukemia (AML)
• A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma Recruiting
  2024-513077-48-00 5 2024-12-19 O6-methylguanine methyltransferase (MGMT) unmethylated glioblastoma
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4 … Recruiting
  2022-502825-17-00 4 2024-10-07 Melanoma
• AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting
  2023-504214-30-00 5 2024-06-27 Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
• A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c … Recruiting
  2023-507402-13-00 5 2024-04-03 Multiple myeloma
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di … Recruiting
  2023-507518-28-00 5 2022-09-13 Acute myeloid leukemia
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 Patients with newly diagnosed, histologically confirmed, primary advan
• A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU … Recruiting
  2023-506414-46-00 5 2022-04-22 High risk patients defined as having at least one of the following ris
• A Long-term Follow-up Study of Sotatercept for PAH Treatment Recruiting
  2023-509138-21-00 5 2021-08-26 Pulmonary Arterial Hypertension (PAH)
• A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Pri … Recruiting
  2023-508587-29-00 4 2018-04-03 Treatment of high-risk neuroblastoma patients with primary refractory
• ALL SCTped 2012 FORUM - Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia Recruiting
  2024-512657-24-00 10 2014-03-27 Acute Lymphoblastic Leukaemia
• NeoMatryx - Neoadjuvant Merkel cell carcinoma therapy (Tx) with the PD-1 inhibitor Cemiplimab – A randomized, double-blind, placebo-controll … Recruiting
  2025-522091-84-00 4 2026-05-29 Merkel Cell Carcinoma
• A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) Recruiting
  2024-520014-22-00 5 2026-04-22 Locally advanced/metastatic urothelial carcinoma
• LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting
  2025-522338-30-00 4 2026-03-31 Ulcerative Colitis
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 5 2026-03-24 Metastatic castration resistant prostate cancer
• A study to test how well PLENVU®, a bowel cleansing medicine, works in children and teenagers before they have a colonoscopy exam Recruiting
  2025-522046-42-00 5 2026-03-24 Colonic disease
• An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting
  2025-521036-11-00 5 2026-03-23 Immune system disseases
• A Trial of Felzartamab in Recipients of Kidney Transplants with Late Isolated Microvascular Inflammation (MVI) - (TRANSPIRE) Recruiting
  2025-521742-15-00 4 2026-03-03 Treatment of Late Isolated Microvascular Inflammation in Recipients of

Showing 25–48 of 295 trials